Looking beyond these core territories, and as noted in previous calls, we have been building our operations in two additional major countries, Turkey and Brazil. As a result of initial deployment of our field teams, during Q2 Soliris treatment was initiated in a significant number of previously diagnosed PNH patients who had been awaiting therapy with a subsequent one-time positive impact on our results.Read the rest of this transcript for free on seekingalpha.com
Alexion Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.